Education
About Us
Working with TipRanks
Follow Us
Aptose Biosciences (TSE:APS)
TSX:APS
APS Stock Chart & Stats
C$2.08
-C$0.01(-3.08%)
At close: 4:00 PM EST
C$2.08
-C$0.01(-3.08%)
Day’s Range― - ―
52-Week RangeC$1.02 - C$16.50
Previous CloseN/A
Volume48.76K
Average Volume (3M)3.35K
Market Cap
C$5.31M
Enterprise ValueC$16.69M
Total Cash (Recent Filing)C$613.00K
Total Debt (Recent Filing)C$19.02M
Price to Earnings (P/E)―
Beta-1.37
Next Earnings
Mar 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.77
Shares Outstanding2,552,429
10 Day Avg. Volume4,664
30 Day Avg. Volume3,346
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-34.40
Price to Sales (P/S)0.00
P/FCF Ratio-4.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$2.41Price Target Upside15.98% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTuspetinib is a highly differentiated kinase inhibitor with favorable safety and broad activity across difficult-to-treat AML subpopulations, including those with TP53, RAS, and FLT3 mutations.
Financial CollaborationAptose is working with its partner Hanmi Pharmaceutical to negotiate a new tuspetinib co-development collaboration agreement to provide necessary additional funding and accelerate clinical development of tuspetinib.
Bears Say
Cash ReservesThe company ended the year with $6.7 million in cash, which management believes should provide runway for ongoing operations through April 2025.
Aptose Biosciences News
APS FAQ
What was Aptose Biosciences’s price range in the past 12 months?
Aptose Biosciences lowest stock price was C$1.02 and its highest was C$16.50 in the past 12 months.
What is Aptose Biosciences’s market cap?
Aptose Biosciences’s market cap is C$5.31M.
When is Aptose Biosciences’s upcoming earnings report date?
Aptose Biosciences’s upcoming earnings report date is Mar 24, 2026 which is in 93 days.
How were Aptose Biosciences’s earnings last quarter?
Aptose Biosciences released its earnings results on Nov 13, 2025. The company reported -C$2.773 earnings per share for the quarter, missing the consensus estimate of N/A by -C$2.773.
Is Aptose Biosciences overvalued?
According to Wall Street analysts Aptose Biosciences’s price is currently Undervalued.
Does Aptose Biosciences pay dividends?
Aptose Biosciences does not currently pay dividends.
What is Aptose Biosciences’s EPS estimate?
Aptose Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aptose Biosciences have?
Aptose Biosciences has 2,552,429 shares outstanding.
What happened to Aptose Biosciences’s price movement after its last earnings report?
Aptose Biosciences reported an EPS of -C$2.773 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.577%.
Which hedge fund is a major shareholder of Aptose Biosciences?
Currently, no hedge funds are holding shares in TSE:APS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
APS Stock 12 Month Forecast
Average Price Target
C$2.41
▲(15.98% Upside)
Technical Analysis
XORTX Therapeutics Inc
―
Kane Biotech
―
Quest Pharmatech
―
BetterLife Pharma
―
BioVaxys Technology
―
Options Prices
Currently, No data available
---